Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

WuXi PharmaTech COO Highlights Growth

publication date: Feb 25, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
WuXi PharmaTech plans to continue its growth by expanding into biotech, safety evaluation and manufacturing. In fact, to make the growth a reality, the company invests about $60 million each year in capital expenditures. "The majority of our clients are big international firms, with Pfizer and Merck ranking as the top two,” said Edward Hu, COO of the WuXi PharmaTech in a recent interview. More details...

Stock Symbol: (NYSE: WX)



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at this event:
 
 
Hope to see you there!
 
ChinaBio® Events
 
China Forum 2014

Frankfurt, Germany
November 2, 2014

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors